A PHASE I CLINICAL TRIAL TO EVALUATE: PART A. THE SAFETY OF MTP-PE/MF59 ADJUVANT EMULSION. PART B. THE SAFETY AND IMMUNOGENICITY OF ENV 2-3, A YEAST DERIVED RECOMBINANT ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS-1, IN COMBINATION WITH MTP-PE/MF59: